SCHEMBL1203883

SCHEMBL1203883

CCOC(=O)c1cccc(NCC(=O)c2cnc3ccc(N(C)Cc4ccc(OC)cc4)nn23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ LMNA P02545 2/20 0.39
▸ CDC25B P30305 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CDC25A P30304 1/20 0.39
▸ CDC25C P30307 1/20 0.39
▸ TP53 P04637 2/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ DYRK3 O43781 1/20 0.38
▸ CCNT1 O60563 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CDK5 Q00535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203271 0.89 KMT2A (0.48) MAPTKMT2ALMNATSHRMAPK1
SCHEMBL1203713 0.85 PIM1 (0.50) MAPTKMT2ALMNACDC25BTSHR
SCHEMBL1203885 0.84 MEN1 (0.39) MAPTKMT2ALMNAMEN1DYRK3
SCHEMBL1203586 0.83 EGFR (0.47) MAPTKMT2ALMNACDC25BTSHR
SCHEMBL1203562 0.78 MAPT (0.41) MAPTKMT2ALMNACDC25BTSHR
SCHEMBL1203201 0.77 NTRK1 (0.47) MAPTKMT2ALMNAMAPK1MEN1
SCHEMBL1202379 0.75 NTRK1 (0.47) MAPTKMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL1203076 0.75 PIM1 (0.51) MAPTKMT2ALMNATSHRMAPK1
SCHEMBL1202900 0.74 PPARD (0.46) MAPTKMT2ALMNAMEN1FYN
SCHEMBL1203715 0.72 PIM1 (0.49) DYRK3CCNT1CCNA2CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 MAPT 3988/4885KMT2A 1247/4885LMNA 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback